Johnson & Johnson (JNJ) reported $24.06 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 9.9%. EPS of $2.70 for the same period compares to $2.77 a year ago.
The reported revenue represents a surprise of +2.63% over the Zacks Consensus Estimate of $23.45 billion. With the consensus EPS estimate being $2.67, the EPS surprise was +1.07%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Johnson & Johnson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic Sales Growth (Operational growth): 6.4% compared to the 7% average estimate based on three analysts. Sales- Innovative Medicine- Oncology- CARVYKTI- WW: $597 million versus $587.77 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +61.8% change. Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW: $468 million versus $496.51 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +46.3% change. Sales- International: $10.73 billion compared to the $10.26 billion average estimate based on three analysts. The reported number represents a change of +11.9% year over year. Sales- MedTech- Cardiovascular- Electrophysiology- WW: $1.49 billion versus $1.48 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.6% change. Sales- MedTech- Total: $8.64 billion compared to the $8.57 billion average estimate based on four analysts. The reported number represents a change of +7.7% year over year. Sales- Innovative Medicine- WW: $15.43 billion versus $15.05 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.2% change. Sales- MedTech- Orthopaedics- Trauma- WW: $833 million versus $800.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change. Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW: $694 million versus $693.01 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change. Sales- MedTech- Surgery- Advanced- WW: $1.12 billion compared to the $1.12 billion average estimate based on three analysts. The reported number represents a change of +4.7% year over year. Sales- MedTech- Surgery- WW: $2.51 billion versus $2.52 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change. Sales- Innovative Medicine- Cardiovascular / Metabolism / Other- Other- WW: $233 million versus $299.82 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -27.9% change.View all Key Company Metrics for Johnson & Johnson here>>>
Shares of Johnson & Johnson have returned -2.2% over the past month versus the Zacks S&P 500 composite's +3.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
SeeWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).